BioXcel Therapeutics is trading 12.9% up now at $0.12, with the move occurring during a broader biotech rebound.
- The biotech sector ETF is up 2.75%, while major U.S. indexes are also higher.
- No new positive company-specific catalyst explains the September 3, 2026 move.
- Recent developments remain unfavorable: BioXcel filed Chapter 11 and agreed to a court-supervised asset sale to Teva; Nasdaq initiated delisting proceedings.